Nkarta (NASDAQ:NKTX) Downgraded by Wall Street Zen to “Strong Sell”

Posted by Stanley Muller on Aug 16th, 2026

Wall Street Zen downgraded shares of Nkarta (NASDAQ:NKTX – Free Report) from a sell rating to a strong sell rating in a report released on Saturday morning.

Several other brokerages have also recently weighed in on NKTX. Evercore set a $9.00 target price on Nkarta in a research note on Monday, May 18th. HC Wainwright dropped their price target on shares of Nkarta to $14.00 and set a “buy” rating on the stock in a research report on Tuesday. Stifel Nicolaus cut their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Nkarta in a report on Wednesday, May 13th. Finally, TD Cowen initiated coverage on shares of Nkarta in a research report on Tuesday, June 23rd. They set a “buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Nkarta has an average rating of “Moderate Buy” and a consensus price target of $11.20.

View Our Latest Report on NKTX

Nkarta Price Performance

NKTX opened at $2.33 on Friday. The business has a 50 day moving average price of $2.64 and a two-hundred day moving average price of $2.58. The company has a market capitalization of $166.87 million, a price-to-earnings ratio of -1.48 and a beta of 0.93. Nkarta has a 1-year low of $1.70 and a 1-year high of $3.72.

Nkarta (NASDAQ:NKTX – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.18). Equities analysts expect that Nkarta will post -1.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Nkarta

A number of hedge funds have recently modified their holdings of NKTX. BlackRock Inc. acquired a new stake in shares of Nkarta during the second quarter worth $17,830,000. GSK plc acquired a new position in shares of Nkarta in the 4th quarter valued at $5,829,000. Monaco Asset Management SAM boosted its position in shares of Nkarta by 29.2% in the 4th quarter. Monaco Asset Management SAM now owns 2,546,932 shares of the company’s stock valued at $4,712,000 after purchasing an additional 576,022 shares during the period. Renaissance Technologies LLC increased its stake in Nkarta by 1.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,732,372 shares of the company’s stock worth $3,655,000 after purchasing an additional 30,350 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Nkarta by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock worth $2,006,000 after purchasing an additional 10,065 shares in the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Key Nkarta News

Here are the key news stories impacting Nkarta this week:

Positive Sentiment: Stifel maintains a bullish view: Stifel Nicolaus lowered its price target from $11 to $10 but initiated or reaffirmed a “Buy” rating. The revised target still implies approximately 329% upside from the referenced $2.33 share price, providing a positive catalyst for Nkarta (NKTX). Ticker Report article
Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: The firm reduced its EPS forecasts for the third and fourth quarters of 2026 to losses of $0.46 and $0.48, respectively, and lowered its full-year estimates to losses of $1.86 in 2026, $2.26 in 2027, $1.76 in 2028, $1.53 in 2029 and $1.23 in 2030. These revisions indicate expectations for deeper or more persistent losses, which may pressure NKTX despite HC Wainwright retaining its “Buy” rating and $14 price target. MarketBeat analyst estimates article

About Nkarta

(Get Free Report)

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.